Back to results

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

Primary Purpose

BRCA or HRR+ Mutated Ovarian Cancer Patients

Status

Completed

Phase

Phase 4

Locations

International

Study Type

Interventional

Intervention

Olaparib

About this trial

This is an interventional other trial for BRCA or HRR+ Mutated Ovarian Cancer Patients

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Provision of informed consent prior to any study specific procedures
Age 18 years or over
Documented germline or somatic mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) [Genetic counselling for patients with germline BRCA mutations should be performed according to local regulations] Or Tumour BRCAwt status and documented qualifying mutation in any of 13 genes involved in the HRR pathway, excluding BRCA1 and BRCA2 (ATM, BARD1, BRIP1,CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D,and RAD54L), identified by the Lynparza HRR Assay in archival tumour tissue (i.e.,BRCA-independent HRRm)
Patients with platinum sensitive relapsed high grade epithelial ovarian cancers (including primary peritoneal and/or fallopian tube cancer):
- Platinum sensitive disease is defined as disease progression ≥6 months after completion of their last dose of platinum based chemotherapy
Patients should have received at least 2 previous lines of platinum containing therapy prior to enrolment:
- For the last chemotherapy course immediately prior to enrolment on the study, patients must be, in the opinion of the investigator, in response (partial or complete radiological response) and no evidence of a rising CA-125, following completion of this chemotherapy course.
Patients must have normal organ and bone marrow function measured within 28 days of enrolment, as defined below:
- Haemoglobin ≥ 10.0 g/dL with no blood transfusions in the past 28 days
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase [SGOT]) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase [SGPT]) ≤ 2.5 x institutional ULN unless liver metastases are present in which case they must be ≤ 5x ULN
Creatinine clearance > 50 ml/min (calculated)
Patients must be postmenopausal or have evidence of non-childbearing status for women of childbearing potential.

Postmenopausal is defined as any of the following:

Amenorrhoea for 1 year or more following cessation of exogenous hormonal treatments
For women under 50 years old, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range
Radiation-induced oophorectomy, with interval of 1 year or more since last menses
Chemotherapy-induced menopause, with interval of 1 year or more since last menses
Surgical sterilisation (bilateral oophorectomy or hysterectomy).

Exclusion Criteria:

Patients previously diagnosed with gBRCAm disease
Participation in another clinical study with an investigational product during the most recent chemotherapy course
Patients with a known hypersensitivity to olaparib or any of the excipients of the product
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) or major surgery within 3 weeks prior to olaparib treatment. Major surgery within 3 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Persistent toxicities Common Terminology Criteria for Adverse Event (CTCAE) grade 2 caused by previous cancer therapy, excluding alopecia
Patients with myelodysplastic syndrome/acute myeloid leukaemia
Immuno-compromised patients e.g., Human Immunodeficiency Virus (HIV) requiring treatment or active Hepatitis B or C
Patients with symptomatic uncontrolled brain metastases. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days
Patients considered to be at a high medical risk due to a serious, uncontrolled medical disorder, systemic disease or active, uncontrolled infection
Currently pregnant (confirmed with a positive pregnancy test) or breastfeeding.

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Olaparib

Arm Description

Open Label Drug

Outcomes

Primary Outcome Measures

Progression-Free Survival (PFS)

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS. The PFS was defined as the time from the date of enrolment until date of objective radiological disease progression (assessed by the Investigator via Response Evaluation Criteria in Solid Tumors, version 1.1 [RECIST 1.1]), or death (by any cause in absence of disease progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to disease progression. Objective progression was defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) and an absolute increase of > 5 millimeters, or an overall non-target lesion assessment of progression or a new lesion. The data cut-off (DCO) for the primary analysis of the study occurred after approximately 60% maturity of PFS in the sBRCAm and all BRCAm patient populations.

Secondary Outcome Measures

Overall Survival (OS); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of OS. The OS was defined as the time from the date of enrolment until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Pre-specified analysis of OS was performed at the time of primary analysis of PFS; a further analysis of OS was performed after approximately 60% maturity of OS in the sBRCAm and all BRCAm patient populations (and reported as a separate outcome measure).

Time to Second Progression (PFS2) or Death; Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS2. The PFS2 was defined as the time from the date of enrolment to the earliest progression event subsequent to that used for the primary variable PFS or death (by any cause) in the absence of progression. Patients whose progression event for PFS was death had this counted as a progression event for PFS2 also. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of the following: objective radiological, symptomatic, cancer antigen-125 (CA-125) progression or death. Pre-specified analysis of PFS2 was performed at the time of the primary analysis; a further analysis of PFS2 was performed at the final analysis (and reported as a separate outcome measure).

Time to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TFST. The TFST was defined as the time from the date of enrolment to the earlier of first subsequent anti-cancer therapy start date (excluding radiotherapy), or death date. Pre-specified analysis of TFST was performed at the time of the primary analysis; a further analysis of TFST was performed at the final analysis (and reported as a separate outcome measure).

Time to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TSST. The TSST was defined as the time from the date of enrolment to the earlier of the date of second subsequent anti-cancer therapy start date, or death date. Pre-specified analysis of TSST was performed at the time of the primary analysis; a further analysis of TSST was performed at the final analysis (and reported as a separate outcome measure).

Time to Discontinuation of Treatment or Death (TDT)

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TDT. The TDT was defined as the time from the date of enrolment to the earlier of the date of study treatment discontinuation or death.

Change From Baseline in Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) Scores Over Time

To assess the Quality of Life (QoL) of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACT-O TOI. The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire version 4. The FACT-O TOI score ranges from 0-100, with a higher score indicating better QoL. A change (increase or decrease) in score of at least 10 points from baseline was defined as clinically meaningful. A positive change in score from baseline indicates an improvement.

Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores Over Time

To assess the QoL of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACIT-F. The FACIT-F is a 13-item questionnaire to assess patients' fatigue experience and its impact on their daily lives over the past 7 days. The FACIT-F total score ranges from 0-52, with a higher score indicating a lower level of fatigue (and better QoL). Changes in scores of ≥3 points were defined to be clinically meaningful. A positive change in score from baseline indicates an improvement.

Change From Baseline in Functional Living Index-Emesis (FLIE) Questionnaire Total Scores Over Time

The FLIE captures the impact of nausea and vomiting on patient's QoL. The FLIE consists of 18 items (9 nausea-specific and 9 vomiting-specific items), rated from 1 to 7. Two domain scores and a total score are derived; the total score ranges 18-126 and a higher score indicates a lower impact (and better QoL). A positive change in score from baseline indicates an improvement.

OS; Assessed at Final Analysis

PFS2 or Death; Assessed at Final Analysis

TFST; Assessed at Final Analysis

TSST; Assessed at Final Analysis

Full Information

NCT ID

NCT02476968

First Posted

June 10, 2015

Last Updated

August 17, 2022

Sponsor

AstraZeneca

1. Study Identification

Unique Protocol Identification Number

NCT02476968

Brief Title

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Acronym

ORZORA

Official Title

An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA).

Study Type

Interventional

2. Study Status

Record Verification Date

August 2022

Overall Recruitment Status

Completed

Study Start Date

September 28, 2015 (Actual)

Primary Completion Date

April 17, 2020 (Actual)

Study Completion Date

December 17, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

AstraZeneca

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

This is a prospective, open-label, single arm, multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation (in line with the EU approved prescribing information) and will be conducted in platinum-sensitive relapsed high grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) who carry germline or somatic BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious [known or predicted to be detrimental/lead to loss of function]).

Detailed Description

The study will recruit approximately 250 patients with sBRCAm disease or gBRCAm disease, with the aim to accrue a minimum of 50 patients with sBRCAm disease. Patients with an unknown germline BRCA mutated status or gBRCAwt disease or previously identified as having a BRCAm disease by a tumour test will be considered for screening and will undergo, upon informed consent signature, central tumor and blood testing to determine their BRCA mutation status. In addition to central BRCA testing, patients screened for the study with unknown BRCA status or with known gBRCAwt status, for whom an adequate archival tumour tissue sample is available, will be tested for qualifying HRR gene alterations. Patients confirmed to carry a deleterious or suspected deleterious BRCA-independent genetic alteration in any of 13 genes involved in the Homologous Recombination Repair (HRR) pathway (HRRm cohort) will be allowed into an additional exploratory cohort (HRRm cohort). It is expected that approximately 25 patients will be included in the HRRm cohort before the target number of 250 patients with BRCAm disease is reached. Patients will be assigned olaparib capsules orally 400 mg twice daily. They should initiate olaparib treatment within 8 weeks after their last dose of platinum-containing chemotherapy (last dose is the day of the last infusion) and will be assessed every 4 weeks whilst on treatment. All patients will have clinical and objective radiological tumour assessments according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines at baseline and every 12 weeks relative to date of enrolment, until objective radiological disease progression as determined by the investigator. Patients could continue to receive olaparib for as long as determined by the investigator, until objective radiological disease progression or as long as in the investigator's opinion they are benefiting from treatment in relation to other clinical assessments and they do not meet any other discontinuation criteria. Once a patient has discontinued olaparib she will be managed as per local clinical practice but will remain in the study and data will be collected on subsequent treatments, progression, overall survival and safety. For exploratory analysis purposes, patients will be asked to provide consent to: Optional tumour samples at baseline and at disease progression An optional blood sample only for patients with a confirmed sBRCAm or HRRm disease

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

BRCA or HRR+ Mutated Ovarian Cancer Patients

7. Study Design

Primary Purpose

Other

Study Phase

Phase 4

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

181 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Olaparib

Arm Type

Other

Arm Description

Open Label Drug

Intervention Type

Drug

Intervention Name(s)

Olaparib

Other Intervention Name(s)

Lynparza

Intervention Description

Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage. Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily. Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water.

Primary Outcome Measure Information:

Title

Progression-Free Survival (PFS)

Description

Time Frame

Tumour assessments at baseline then every 12 weeks relative to date of enrolment until RECIST 1.1-defined progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Secondary Outcome Measure Information:

Title

Overall Survival (OS); Assessed at Primary Analysis

Description

Time Frame

From baseline until death due to any cause. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Title

Time to Second Progression (PFS2) or Death; Assessed at Primary Analysis

Description

Time Frame

Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Title

Time to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis

Description

Time Frame

From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Title

Time to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis

Description

Time Frame

From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Title

Time to Discontinuation of Treatment or Death (TDT)

Description

Time Frame

From enrolment to study treatment discontinuation or death (up to maximum of 6 years).

Title

Change From Baseline in Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) Scores Over Time

Description

Time Frame

QoL questionnaires at baseline, Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. QoL questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.

Title

Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores Over Time

Description

Time Frame

Title

Change From Baseline in Functional Living Index-Emesis (FLIE) Questionnaire Total Scores Over Time

Description

Time Frame

FLIE questionnaires at baseline, weekly until Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. FLIE questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.

Title

OS; Assessed at Final Analysis

Description

Time Frame

From baseline until death due to any cause (up to maximum of 6 years).

Title

PFS2 or Death; Assessed at Final Analysis

Description

Time Frame

Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression (up to maximum of 6 years).

Title

TFST; Assessed at Final Analysis

Description

Time Frame

From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).

Title

TSST; Assessed at Final Analysis

Description

Time Frame

From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).

10. Eligibility

Sex

Female

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

130 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Provision of informed consent prior to any study specific procedures Age 18 years or over Documented germline or somatic mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) [Genetic counselling for patients with germline BRCA mutations should be performed according to local regulations] Or Tumour BRCAwt status and documented qualifying mutation in any of 13 genes involved in the HRR pathway, excluding BRCA1 and BRCA2 (ATM, BARD1, BRIP1,CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D,and RAD54L), identified by the Lynparza HRR Assay in archival tumour tissue (i.e.,BRCA-independent HRRm) Patients with platinum sensitive relapsed high grade epithelial ovarian cancers (including primary peritoneal and/or fallopian tube cancer): - Platinum sensitive disease is defined as disease progression ≥6 months after completion of their last dose of platinum based chemotherapy Patients should have received at least 2 previous lines of platinum containing therapy prior to enrolment: - For the last chemotherapy course immediately prior to enrolment on the study, patients must be, in the opinion of the investigator, in response (partial or complete radiological response) and no evidence of a rising CA-125, following completion of this chemotherapy course. Patients must have normal organ and bone marrow function measured within 28 days of enrolment, as defined below: Haemoglobin ≥ 10.0 g/dL with no blood transfusions in the past 28 days Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase [SGOT]) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase [SGPT]) ≤ 2.5 x institutional ULN unless liver metastases are present in which case they must be ≤ 5x ULN Creatinine clearance > 50 ml/min (calculated) Patients must be postmenopausal or have evidence of non-childbearing status for women of childbearing potential. Postmenopausal is defined as any of the following: Amenorrhoea for 1 year or more following cessation of exogenous hormonal treatments For women under 50 years old, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range Radiation-induced oophorectomy, with interval of 1 year or more since last menses Chemotherapy-induced menopause, with interval of 1 year or more since last menses Surgical sterilisation (bilateral oophorectomy or hysterectomy). Exclusion Criteria: Patients previously diagnosed with gBRCAm disease Participation in another clinical study with an investigational product during the most recent chemotherapy course Patients with a known hypersensitivity to olaparib or any of the excipients of the product Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) or major surgery within 3 weeks prior to olaparib treatment. Major surgery within 3 weeks of starting study treatment and patients must have recovered from any effects of any major surgery Persistent toxicities Common Terminology Criteria for Adverse Event (CTCAE) grade 2 caused by previous cancer therapy, excluding alopecia Patients with myelodysplastic syndrome/acute myeloid leukaemia Immuno-compromised patients e.g., Human Immunodeficiency Virus (HIV) requiring treatment or active Hepatitis B or C Patients with symptomatic uncontrolled brain metastases. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days Patients considered to be at a high medical risk due to a serious, uncontrolled medical disorder, systemic disease or active, uncontrolled infection Currently pregnant (confirmed with a positive pregnancy test) or breastfeeding.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Sandro Pignata, Doctor of Medicine

Organizational Affiliation

Istituto Nazionale Tumori Fondazione G. Pascale, 80131, Napoli, Italy

Official's Role

Principal Investigator

Facility Information:

Facility Name

Research Site

City

Plovdiv

ZIP/Postal Code

4000

Country

Bulgaria

Facility Name

Research Site

City

Plovdiv

ZIP/Postal Code

4004

Country

Bulgaria

Facility Name

Research Site

City

Sofia

ZIP/Postal Code

1303

Country

Bulgaria

Facility Name

Research Site

City

Sofia

ZIP/Postal Code

1330

Country

Bulgaria

Facility Name

Research Site

City

Sofia

ZIP/Postal Code

1407

Country

Bulgaria

Facility Name

Research Site

City

Sofia

ZIP/Postal Code

1756

Country

Bulgaria

Facility Name

Research Site

City

Varna

ZIP/Postal Code

9010

Country

Bulgaria

Facility Name

Research Site

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4N2

Country

Canada

Facility Name

Research Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 2E2

Country

Canada

Facility Name

Research Site

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 4L6

Country

Canada

Facility Name

Research Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5G 1X6

Country

Canada

Facility Name

Research Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H2X 0A9

Country

Canada

Facility Name

Research Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3T 1E2

Country

Canada

Facility Name

Research Site

City

Brno

ZIP/Postal Code

625 00

Country

Czechia

Facility Name

Research Site

City

Brno

ZIP/Postal Code

656 53

Country

Czechia

Facility Name

Research Site

City

Novy Jicin

ZIP/Postal Code

741 01

Country

Czechia

Facility Name

Research Site

City

Olomouc

ZIP/Postal Code

775 20

Country

Czechia

Facility Name

Research Site

City

Ostrava

ZIP/Postal Code

708 52

Country

Czechia

Facility Name

Research Site

City

Praha 2

ZIP/Postal Code

128 08

Country

Czechia

Facility Name

Research Site

City

Praha 5

ZIP/Postal Code

15000

Country

Czechia

Facility Name

Research Site

City

Budapest

ZIP/Postal Code

1032

Country

Hungary

Facility Name

Research Site

City

Budapest

ZIP/Postal Code

1062

Country

Hungary

Facility Name

Research Site

City

Budapest

ZIP/Postal Code

1122

Country

Hungary

Facility Name

Research Site

City

Debrecen

ZIP/Postal Code

4032

Country

Hungary

Facility Name

Research Site

City

Kecskemét

ZIP/Postal Code

6000

Country

Hungary

Facility Name

Research Site

City

Nyíregyháza

ZIP/Postal Code

4400

Country

Hungary

Facility Name

Research Site

City

Bari

ZIP/Postal Code

70124

Country

Italy

Facility Name

Research Site

City

Milano

ZIP/Postal Code

20141

Country

Italy

Facility Name

Research Site

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

Research Site

City

Perugia

ZIP/Postal Code

06132

Country

Italy

Facility Name

Research Site

City

Bialystok

ZIP/Postal Code

15-027

Country

Poland

Facility Name

Research Site

City

Gdansk

ZIP/Postal Code

80-402

Country

Poland

Facility Name

Research Site

City

Kielce

ZIP/Postal Code

25-734

Country

Poland

Facility Name

Research Site

City

Poznan

ZIP/Postal Code

60-569

Country

Poland

Facility Name

Research Site

City

Poznań

Country

Poland

Facility Name

Research Site

City

Badalona

ZIP/Postal Code

08916

Country

Spain

Facility Name

Research Site

City

Barcelona

ZIP/Postal Code

08025

Country

Spain

Facility Name

Research Site

City

Burgos

ZIP/Postal Code

09006

Country

Spain

Facility Name

Research Site

City

L'Hospitalet de Llobregat

ZIP/Postal Code

08908

Country

Spain

Facility Name

Research Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Research Site

City

Madrid

ZIP/Postal Code

28041

Country

Spain

Facility Name

Research Site

City

San Cristobal de La Laguna

ZIP/Postal Code

38320

Country

Spain

Facility Name

Research Site

City

Sevilla

ZIP/Postal Code

41009

Country

Spain

Facility Name

Research Site

City

Valencia

ZIP/Postal Code

46010

Country

Spain

Facility Name

Research Site

City

Valencia

ZIP/Postal Code

46026

Country

Spain

Facility Name

Research Site

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

Research Site

City

Belfast

ZIP/Postal Code

BT9 7AB

Country

United Kingdom

Facility Name

Research Site

City

Birmingham

ZIP/Postal Code

B18 7QH

Country

United Kingdom

Facility Name

Research Site

City

Cardiff

ZIP/Postal Code

CF14 2TL

Country

United Kingdom

Facility Name

Research Site

City

Glasgow

ZIP/Postal Code

G12 OYN

Country

United Kingdom

Facility Name

Research Site

City

Leeds

ZIP/Postal Code

LS9 7TF

Country

United Kingdom

Facility Name

Research Site

City

London

ZIP/Postal Code

SE1 9RT

Country

United Kingdom

Facility Name

Research Site

City

Manchester

ZIP/Postal Code

M20 4BX

Country

United Kingdom

Facility Name

Research Site

City

Newcastle upon Tyne

ZIP/Postal Code

NE7 7DN

Country

United Kingdom

Facility Name

Research Site

City

Oxford

ZIP/Postal Code

OX3 7LJ

Country

United Kingdom

Facility Name

Research Site

City

Swansea

ZIP/Postal Code

SA2 8QA

Country

United Kingdom

Facility Name

Research Site

City

Taunton

ZIP/Postal Code

TA1 5DA

Country

United Kingdom

Facility Name

Research Site

City

Wirral

ZIP/Postal Code

CH63 4JY

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing URL

https://astrazenecagroup-dt.pharmacm.com/DT/Home

Links:

URL

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D0816C00012&attachmentIdentifier=17120550-7e5c-4a45-b05e-ad52fb65aab0&fileName=D0816C00012-SAP-ed5_Final_Redacted.pdf&versionIdentifier=

Description

Redacted SAP

URL

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D0816C00012&attachmentIdentifier=4dc4c1bf-d982-4b95-a291-060c8a5e1633&fileName=D0816C00012-CSP-v3_Final_Redacted.pdf&versionIdentifier=

Description

Redacted CSP

URL

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D0816C00012&attachmentIdentifier=71181818-9e35-43f9-b5a0-b802bb6b1488&fileName=D0816c00012-synopsis_Primary_Analysis_Redacted_Final_PDFA.pdf&versionIdentifier=

Description

Synopsis_Primary

URL

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D0816C00012&attachmentIdentifier=3988fabf-e95e-41ed-a348-aff3f5a86620&fileName=D0816c00012-synopsis_Redacted_Final_PDFA.pdf&versionIdentifier=

Description

Synopsis

Learn more about this trial

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

We'll reach out to this number within 24 hrs

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

BRCA or HRR+ Mutated Ovarian Cancer Patients

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial